ACHE and Alzheimer disease: As mentioned above, the main drugs currently approved by the FDA for the treatment of Alzheimer’s disease, AchE, and NMDAR inhibitors, are administered orally, so high doses are required for the therapeutic fraction to reach the brain and overcome oral absorption barriers, hepatic metabolism, and finally cross the BBB [326,327,328].